Citigroup maintains Bausch & Lomb at Buy, raises price target to $23 from $21

Citigroup reaffirmed its Buy rating for Bausch & Lomb and increased its price target to $23 from $21, suggesting a 12.7% upside from the last close. Recent analyst price targets for the company range from $19 to $24.

Original reporting
Published Oct 29, 2026, 7:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Bausch & Lomb at Buy, raises price target to $23 from $21 — source image
Decision brief

The 30-second read

$BHCBullishLow
01

Why it matters

The upgrade may prompt short‑term buying but lacks fundamental catalyst.

02

Market read

Analyst target raise provides a modest trading signal for BHC.

03

What to watch

No new earnings data accompanies the upgrade; the move relies on analyst opinion alone.

Relevance 5/10Novelty 5/10Timing: today

Background

Citigroup's analyst note updates its valuation for Bausch & Lomb, a mid‑cap health‑care company.

Company-level read

Ticker impact

$BHCBullishMedium confidence
Context

Citigroup raised its price target on Bausch & Lomb to $23 from $21, indicating a new bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The price target increase suggests improved expectations, which can attract short‑term buyers.

Market effects

May lift sentiment in the ophthalmic and consumer health sector.

Limited to US markets where BHC trades.

Minimal global impact.

Counterpoint

The target raise could be premature if underlying earnings do not improve.

Key entities

  • Bausch & Lomb

    Ophthalmic and consumer health products manufacturer.

  • Citigroup

    Investment bank providing the price target upgrade.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$BHCHighAI 8/10

Bausch Health Companies Inc (BHC) Q3 2026 Earnings Call Highlights: Adjusted EBITDA Tops

Bausch Health (BHC) reported Q3 2026 earnings, raising full-year guidance. Adjusted EBITDA exceeded $1B. CFO JJ Sharon noted a $100M+ impact from Xifaxan price adjustments. CEO Thomas Appio discussed Solta's growth and regulatory timelines. Salix revenue rose 16% to $831M, driven by Xifaxan. The company reduced debt by $521M and announced a $50M share repurchase program.